Printer Friendly

ALKERMES NAMES DR. WILLIAM F. GRANEY VICE PRESIDENT OF MEDICAL AFFAIRS

ALKERMES NAMES DR. WILLIAM F. GRANEY VICE PRESIDENT OF MEDICAL AFFAIRS
 CAMBRIDGE, Mass., April 27 /PRNewswire/ -- Alkermes, Inc. (NASDAQ: ALKS) today announced the appointment of William F. Graney, M.D., as vice president of medical affairs.
 Dr. Graney comes to Alkermes from Rhone-Poulenc Rorer, Collegeville, Pa., where he held the position of group director, clinical research. Prior to Rhone-Poulenc, Dr. Graney was a clinical research director with E.R. Squibb and Sons, Inc.
 "Our strategy is to build an outstanding clinical development and regulatory capability to enable the most efficient testing and regulatory review of our products," said Richard Pops, president and chief executive officer of Alkermes. "Dr. Graney brings to Alkermes extensive experience in building and managing first-class clinical research teams and interacting with the FDA to enable the approval of novel drugs," Pops said. "His drive, intellect and creativity will make him a key contributor to our continued success."
 In his new position, Dr. Graney will be responsible for developing Alkermes' clinical research and data analysis teams, as well as interacting with the FDA. Alkermes currently is conducting Phase I trials of its lead


product, RMP-7. The company intends to commence Phase I/II trials of RMP-7 in several indications, including brain tumor and infectious diseases of the central nervous system. Alkermes is also developing compounds with potential use in acute neurodegenerative diseases, such as stroke, and chronic neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease.
 Dr. Graney, 42 years old, received his undergraduate degree from the University of Delaware and earned his M.D. degree from the University of Pennsylvania.
 Alkermes, Inc. is a neuropharmaceutical company founded in 1987 that is focused on the development and commercialization of therapeutic and diagnostic products for the treatment of disorders of the central nervous system.
 -0- 4/27/92
 /CONTACT: Richard F. Pops, president and chief executive officer, 617-494-0171 of Alkermes; Thomas A. Pearson of Pearson Communications, 215-644-4420, for Alkermes/
 (ALKS) CO: Alkermes, Inc. ST: Massachusetts IN: MTC SU: PER


DD -- NE010 -- 3253 04/27/92 14:07 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 27, 1992
Words:340
Previous Article:GROUNDWATER CLEANUP IN THE SOUTH BAY: A 10-YEAR PERSPECTIVE JOINTLY SPONSORED BY LOCAL ORGANIZATIONS AND STATE AND FEDERAL AGENCIES
Next Article:RECORD WEATHER REFLECTED IN WILLIAMS' FIRST-QUARTER 1992 RESULTS


Related Articles
SEARCH COMMISSION TO SEEK NEW VA UNDER SECRETARY FOR HEALTH
BARRY BLOOM TO RETIRE FROM PFIZER; JOHN NIBLACK NAMED EXECUTIVE VICE PRESIDENT -- R&D
IMMUNOGEN, INC. NAMES CAROL A. GLOFF VICE PRESIDENT OF REGULATORY AFFAIRS
CEPHALON APPOINTS GRANEY VICE PRESIDENT, CLINICAL OPERATIONS
CEPHALON APPOINTS COLIN MARKLAND MEDICAL DIRECTOR, EUROPE
CombinatoRx Announces Key Leadership Appointments; New Executives Come from Ranks of Major Pharmaceutical and Biotech Companies.
BIO Names Chairman, Board Members for 2005-2006.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters